TriSalus Life Sciences (NASDAQ:TLSI – Get Free Report) and Utah Medical Products (NASDAQ:UTMD – Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, dividends, analyst recommendations, risk, institutional ownership, earnings and valuation.
Profitability
This table compares TriSalus Life Sciences and Utah Medical Products’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| TriSalus Life Sciences | N/A | N/A | -221.65% |
| Utah Medical Products | 33.40% | 13.06% | 12.30% |
Risk & Volatility
TriSalus Life Sciences has a beta of 0.55, meaning that its stock price is 45% less volatile than the S&P 500. Comparatively, Utah Medical Products has a beta of 0.14, meaning that its stock price is 86% less volatile than the S&P 500.
Analyst Recommendations
This is a summary of recent ratings and recommmendations for TriSalus Life Sciences and Utah Medical Products, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| TriSalus Life Sciences | 0 | 0 | 3 | 0 | 3.00 |
| Utah Medical Products | 0 | 0 | 0 | 0 | N/A |
TriSalus Life Sciences presently has a consensus target price of $13.33, indicating a potential upside of 129.10%. Given TriSalus Life Sciences’ higher probable upside, research analysts plainly believe TriSalus Life Sciences is more favorable than Utah Medical Products.
Earnings & Valuation
This table compares TriSalus Life Sciences and Utah Medical Products’ gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| TriSalus Life Sciences | $21.98 million | 7.19 | -$59.04 million | N/A | N/A |
| Utah Medical Products | $50.22 million | 4.68 | $16.64 million | $4.50 | 14.79 |
Utah Medical Products has higher revenue and earnings than TriSalus Life Sciences.
Institutional and Insider Ownership
2.6% of TriSalus Life Sciences shares are held by institutional investors. Comparatively, 69.6% of Utah Medical Products shares are held by institutional investors. 76.2% of TriSalus Life Sciences shares are held by insiders. Comparatively, 6.6% of Utah Medical Products shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Summary
Utah Medical Products beats TriSalus Life Sciences on 6 of the 11 factors compared between the two stocks.
About TriSalus Life Sciences
(Get Free Report)
TriSalus Life Sciences, Inc., a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer. It also develops nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma with liver metastases, hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and locally advanced pancreatic ductal adenocarcinoma. The company serves interventional radiologists, IR technicians, medical oncologists, nursing support, value analysis committee staff, and patients through its sales representatives and sales managers. TriSalus Life Sciences, Inc. was founded in 2009 and is headquartered in Westminster, Colorado.
About Utah Medical Products
(Get Free Report)
Utah Medical Products, Inc. develops, manufactures, and distributes medical devices for the healthcare industry worldwide. It offers fetal monitoring accessories, vacuum-assisted delivery systems, and other labor and delivery tools; DISPOSA-HOOD infant respiratory hoods; and DELTRAN PLUS blood pressure monitoring systems. It also provides GESCO, an umbilical vessel catheters, including DIALY-NATE disposable peritoneal dialysis sets; PALA-NATE silicone oral protection devices; URI-CATH urinary drainage systems; NUTRI-CATHNUTRI-LOK feeding device; PICC-NATE, a percutaneous intraepithelial central venous catheter; MYELO-NATE lumbar sampling kits; HEMO-NATE disposable filters; and catheterization procedure tray of instruments and supplies. In addition, the company offers LETZ system to excise cervical intraepithelial neoplasia and other lower genital tract lesions; loop, ball, and needle electrodes; FILTRESSE evacuators; other specialty electrodes and supplies, and gynecologic tools; Femcare trocars, cannulae, laparoscopic instruments, and accessories; and EPITOME and OptiMicro electrosurgical devices. Further, it provides Filshie Clip female surgical contraception devices; PATHFINDER PLUS, an endoscopic irrigation devices; suprapubic catheterization; LIBERTY, an urinary incontinence treatment and control systems; ENDOCURETTE, a curette for uterine endometrial tissue sampling; TVUS/HSG-Cath to assess abnormal or dysfunctional uterine bleeding and other abnormalities of uterus; and LUMIN, a tool to manipulate the uterus in laparoscopic procedures. Additionally, it offers DELTRAN, a disposable pressure transducer; high-pressure and piezo-resistive transducer assemblies; and pressure monitoring accessories, components, and other molded parts. It serves neonatal intensive care units, labor and delivery departments, women’s health centers in hospitals, outpatient clinics, and physician’s offices. The company was incorporated in 1978 and is headquartered in Midvale, Utah.
Receive News & Ratings for TriSalus Life Sciences Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for TriSalus Life Sciences and related companies with MarketBeat.com’s FREE daily email newsletter.
